Boston Scientific Corp.(BSX) has been making significant headlines for its steady growth, strategic acquisitions and its promising outlook. Increasing holdings by various investment management firms like Norden Group LLC, Brookstone Capital Management, VCI Wealth Management LLC and Fullerton Fund Management Co Ltd signify a robust investor interest. The company is also viewed as a potential leader in healthcare AI stocks backed by its R&D efforts and AI-enhanced heart devices. An affirmed buy rating from UBS, Canaccord Genuity and RBC Capital further solidify this. Boston Scientific's M&A strategy has also strengthened their growth prospects. The firm is well-positioned for long-term endoscopy growth and has shown impressive sales growth in Q3 2025. We see valuation concerns due to a strong multi-year run, however, they are countered by investor optimism around Farapulse, indicating potential reshaping of investors’ thesis. Analyst visits confirm growth potential, with a focus on IVL market opportunity. However, a recent stock pullback has raised questions on its current valuation.
Boston Scientific Corp BSX News Analytics from Wed, 23 Jul 2025 07:00:00 GMT to Fri, 26 Dec 2025 13:54:55 GMT -
Rating 8
- Innovation 7
- Information 9
- Rumor 4
